Microdose Tirzepatide: New Study Reports 4.4- to 6.9-Pound Average Weight Loss by Day 59

A PlexusDx medRxiv preprint reported average self-reported weight loss of 2.2% (4.4 pounds) after a median 21 days and 3.6% (6.9 pounds) after 48 days among patients using compounded tirzepatide at 1–2 mg weekly. The retrospective 60-patient analysis was unreviewed, lacked a control group, used self-reported weights and had only eight observations at 60–89 days, preventing conclusions on efficacy, safety or equivalence with standard dosing. The compounded tirzepatide-plus-B12 formulation is not FDA-approved, and PlexusDx leadership authored the study.

Analysis

This is not investable efficacy validation, but it is a useful signal that cash-pay telehealth providers will continue testing lower-dose GLP-1 protocols to widen affordability and extend constrained supply. If such protocols gain adoption, the nearer-term economic pressure falls on branded GLP-1 revenue per patient rather than total treated patients: lower starting doses can improve conversion and persistence, but may reduce milligrams dispensed and delay escalation. For Eli Lilly (LLY), the key variable is whether incremental low-dose users are genuinely incremental demand or cannibalize patients who would otherwise initiate branded Zepbound at standard titration.

The more consequential second-order risk is regulatory. A commercial operator publicizing weak, non-comparative evidence around compounded tirzepatide raises the probability of scrutiny of telehealth marketing, pharmacy sourcing, and the distinction between permissible compounding and de facto branded-drug substitution. Hims & Hers (HIMS), Ro, and other cash-pay GLP-1 distributors are exposed to abrupt customer-acquisition disruption if FDA enforcement, state pharmacy boards, or platform policies tighten; this is a 1-6 month headline/regulatory risk rather than a read-through on obesity-drug clinical demand.

Consensus may overstate the immediate negative read-through for LLY and Novo Nordisk (NVO). Lower-dose compounded usage can function as a demand funnel: patients who demonstrate early response may later migrate to regulated branded supply as insurance coverage expands or tolerability management requires formal care. The thesis turns negative for branded manufacturers only if verifiable cash-pay switching coincides with weaker prescription growth, lower net price, or evidence that compounded supply remains durable after shortage-related regulatory flexibility fades.

No broad sector trade is warranted from this release alone. Monitor FDA shortage-list status, enforcement communications, HIMS/Ro customer-acquisition commentary, and LLY/NVO quarterly persistence and realized-price disclosures; those data determine whether compounding is a transient access valve or a lasting price umbrella.

Key Decisions for Investors

• Maintain no incremental position in LLY or NVO on this item; treat any knee-jerk weakness as a watchlist opportunity only if weekly prescription data and next-quarter net-price guidance remain intact.
• For HIMS, avoid adding into strength until management quantifies compounded GLP-1 revenue, sourcing durability, and regulatory contingency plans. A regulatory clarification restricting mass-market compounding would be a downside catalyst over 1-6 months.
• Set an alert for FDA action that removes tirzepatide from shortage-related compounding eligibility or challenges telehealth promotional practices; that would favor LLY relative to cash-pay GLP-1 intermediaries, potentially via long LLY/short HIMS only after confirming material HIMS exposure.
• At LLY and NVO earnings, focus on dose mix, discontinuation/persistence, and net price rather than headline prescription volume. A sustained shift toward lower-dose utilization without volume acceleration would falsify the view that cheaper entry points expand the branded market.